Medical Developments International Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Brent MacGregor

İcra Kurulu Başkanı

AU$6.2m

Toplam tazminat

CEO maaş yüzdesi	9.8%
CEO görev süresi	4yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump

May 13

Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?

May 03

Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge

Mar 11

Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward

Jan 16

Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?

Jan 03

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Aug 09

We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate

Apr 24

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Jul 04

Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

Mar 04

Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates

Mar 05

If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns

Feb 07

Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)

Dec 16

Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Dec 10

CEO Tazminat Analizi

Brent MacGregor'un ücretlendirmesi Medical Developments International'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$6m	AU$602k	-AU$41m
Mar 31 2024	n/a	n/a	-AU$30m
Dec 31 2023	n/a	n/a	-AU$19m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$2m	AU$576k	-AU$6m
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$2m
Sep 30 2022	n/a	n/a	-AU$7m
Jun 30 2022	AU$2m	AU$547k	-AU$12m
Mar 31 2022	n/a	n/a	-AU$16m
Dec 31 2021	n/a	n/a	-AU$19m
Sep 30 2021	n/a	n/a	-AU$16m
Jun 30 2021	AU$1m	AU$351k	-AU$13m

Tazminat ve Piyasa: Brent 'nin toplam tazminatı ($USD 4.09M ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 304.34K ).

Tazminat ve Kazançlar: Brent şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Brent MacGregor (60 yo)

4yrs

Görev süresi

AU$6,166,500

Tazminat

Mr. Brent MacGregor serves as an Independent Director at Dynavax Technologies Corporation since July 2020. He has been the Chief Executive Officer of Medical Developments International Limited since Novemb...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Brent MacGregor	Chief Executive Officer	4yrs	AU$6.17m	0.20% A$ 101.9k
Anita James	Chief Financial Officer	2.5yrs	AU$5.94m	0.056% A$ 28.3k
Matthew Cramer	Chief of Operations & Supply Chain	4.8yrs	Veri yok	Veri yok
Scott Courtney	Chief Scientific Officer	5.3yrs	Veri yok	Veri yok
Tara Eaton	General Counsel & Company Secretary	2.3yrs	Veri yok	Veri yok
Wai Chi	Head of Regulatory Affairs	6yrs	Veri yok	Veri yok
Wayne Pearce	Head of Production	4.3yrs	Veri yok	Veri yok
Stefaan Schatteman	Head of Europe	4.3yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: MVP 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gordon Naylor	Non-Executive Chairman	4.1yrs	AU$95.00k	0.84% A$ 427.8k
Mary Sontrop	Non-Executive Director	3.7yrs	AU$60.00k	0.018% A$ 9.3k
Russell Basser	Non-Executive Director	1.2yrs	AU$50.00k	0.014% A$ 7.1k
Leon Hoare	Non-Executive Director	11.2yrs	AU$60.00k	0.055% A$ 27.9k
Richard Betts	Non-Executive Director	3.5yrs	AU$60.00k	0.021% A$ 10.5k
Christine Emmanuel-Donnelly	Non-Executive Director	4.5yrs	AU$60.00k	0.080% A$ 40.8k

3.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: MVP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Medical Developments International Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Medical Developments International Limited, Annual General Meeting, Oct 24, 2024

Medical Developments International Limited, Annual General Meeting, Oct 27, 2023

Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023

No independent directors

Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022

Medical Developments International Limited, Annual General Meeting, Oct 27, 2022

Recent updates

Medical Developments International Limited, Annual General Meeting, Oct 24, 2024

Consensus EPS estimates upgraded to AU$0.033 loss

Full year 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.

Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.

Medical Developments International Limited to Report Q4, 2024 Results on Aug 26, 2024

Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump

Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?

Price target increased by 38% to AU$3.03

New minor risk - Profitability

Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge

Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024

Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward

Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?

Medical Developments International Limited, Annual General Meeting, Oct 27, 2023

Price target decreased by 29% to AU$1.60

Full year 2023 earnings released: AU$0.067 loss per share (vs AU$0.17 loss in FY 2022)

Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023

New minor risk - Financial data availability

Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate

First half 2023 earnings released: EPS: AU$0.032 (vs AU$0.10 loss in 1H 2022)

Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023

Medical Developments International Limited Discontinues China Clinical Trials

No independent directors

Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022

Medical Developments International Limited, Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: AU$0.17 loss per share (vs AU$0.18 loss in FY 2021)

Price target decreased to AU$4.30

Medical Developments International Limited Provides Earnings Guidance for the Fiscal Year 2022 and Revenue Guidance for the Fiscal Year 2023

Medical Developments International Limited to Report Fiscal Year 2022 Results on Aug 26, 2022

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Medical Developments International Limited Appoints Tara Eaton as General Counsel and Company Secretary, Effective August 8, 2022

No independent directors

Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

Medical Developments International Limited Announces That US Food and Drug Administration Lifts Clinical Hold on Penthrox

Consensus forecasts updated

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Medical Developments International Limited to Report Q2, 2022 Results on Feb 24, 2022

Non-Executive Chairman recently bought AU$306k worth of stock

Non-Executive Chairman recently bought AU$1.0m worth of stock

Full year 2021 earnings released: AU$0.18 loss per share (vs AU$0.006 profit in FY 2020)

Medical Developments International Limited Provides Sales Guidance for the Fiscal Year 2022

Price target decreased to AU$6.18

Medical Developments International Limited Announces Earnings Guidance for the Year Ended June 30, 2021

Non-Executive Chairman recently bought AU$534k worth of stock

Medical Developments International Limited Appoints Mary Sontrop as Non-Executive Director

Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates

Analysts lower EPS estimates to -AU$0.037

Revenue and earnings miss expectations

First half 2021 earnings released: AU$0.017 loss per share (vs AU$0.004 profit in 1H 2020)

If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns

New 90-day high: AU$7.18

Price target raised to AU$7.25

Analysts lower EPS estimates to -AU$0.018

Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)

Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Medical Developments International Limited Announces Executive Changes

New 90-day high: AU$6.61

Price target lowered to AU$6.97

Analysts lower EPS estimates to -AU$0.022

Medical Developments International Limited Appoints Brent Macgregor as Chief Executive Officer, Effective November 1, 2020

Analysts update estimates

Medical Developments International Limited Declares No Dividend for the Full Year Ended 30 June 2020

New 90-day low: AU$5.29

New 90-day low - AU$5.76